Methyl jasmonate and breast cancer: what the experiments actually show

There is a scientific thrill in watching one chemical question cross the border between plant biology and cancer biology. Methyl jasmonate gives us that thrill. The task is to keep the experiment in view while the imagination races ahead. In the breast cancer literature examined here, the evidence concerns laboratory systems. These papers do not establish prevention, treatment or improved outcomes in people.

Start with the exact material in the dish

Jasmonic acid and methyl jasmonate are distinct compounds. A paper using methyl jasmonate cannot automatically be retold as a finding about every member of the jasmonate family. The distinction becomes even more important when researchers use plant material that was exposed to methyl jasmonate. The plant can generate a mixture of metabolites. That mixture is a different intervention from the original compound.

In the 2021 New Phytologist paper by Bomer and colleagues, researchers compared direct MeJA with Arabidopsis material and investigated breast cancer cell models including T-47D and MDA-MB-361, alongside MCF10A comparison cells. The plant JA-perception system helped them explore the origin of the observed bioactivities. The experiment is a discovery tool for possible active components. It is not evidence that eating treated plants reduces breast cancer risk. (S07: primary paper)

A cell line is a model with an identity

The 2008 Yeruva paper reports growth and signaling experiments involving MCF-7 and MDA-MB-435. Read each figure with its model attached. Korch and colleagues later documented MDA-MB-435 as a misidentified derivative of the M14 melanoma line. That tissue identity matters: a result in MDA-MB-435 cannot simply be counted as a breast cancer result. It also does not erase a separately measured MCF-7 observation. (S04: primary paper; S09: primary paper)

This is why a responsible literature table needs a model column. Without one, a handful of papers can look like several independent confirmations of a broad medical claim, even when they examine different cells, compounds and endpoints. Ask whether the model was authenticated, whether the paper supplies a comparison model, and whether the conclusion stays within those boundaries.

Mechanisms deserve questions, not slogans

A proposed mechanism is valuable because it gives researchers something to challenge. Does a pathway change before the cell response? Does blocking it alter the response? Does the effect persist when the model changes? A protein signal observed beside reduced viability is a starting point for a causal question.

The 2024 MCF-7 paper examines magnesium, TRPM7 and related cellular measurements. Its indexed abstract contains a Results sentence using antiapoptotic wording, while the title and Conclusion discuss apoptosis. We flag that inconsistency because the full-text clarification was unavailable during this preparation. Quietly smoothing over it would make the literature look more certain than the record supports. (S08: primary paper)

The next discovery needs a precise claim

Our editorial position is simple: let these papers provoke better experiments. Record the compound, cell identity, comparator, exposure context, assay and limitation. Then write the narrowest sentence that faithfully describes the result. That sentence will usually be more useful to a researcher than a claim that jasmonate fights breast cancer.

These selected studies are not a systematic review, and they are not personal medical guidance. They make a case for informed curiosity. The useful next step is to study how a finding could be reproduced and what would be required to test its relevance beyond the laboratory model. The ambition is large. The evidence must remain exact.